Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progression to PD-1 Antibody”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT07070232
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 1,438
Testing effectiveness (Phase 2)Ended earlyNCT04902040
What this trial is testing

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Who this might be right for
Advanced Bladder CarcinomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid Neoplasm+32 more
M.D. Anderson Cancer Center 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT06449209
What this trial is testing

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Who this might be right for
Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
BioNTech SE 110
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Testing effectiveness (Phase 2)Study completedNCT03132636
What this trial is testing

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Who this might be right for
Carcinoma, Basal Cell
Regeneron Pharmaceuticals 138
Testing effectiveness (Phase 2)UnknownNCT04866381
What this trial is testing

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Who this might be right for
Esophageal Squamous Cell CarcinomaProgression to PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital 87